Symposium 15: From Blueprint to Reality: Development, Conversion, and Application in the Common Data Model Approach Among Asia-Pacific Databases
Tracks
Track 4
| Monday, October 14, 2024 |
| 14:00 - 15:30 |
| Faculty of Medicine Building 1 |
Details
Constructing a common data models (CDM) for multinational studies in Asia is essential to provide evidence of drug effectiveness and safety, supporting or challenging results from clinical trials predominantly involving Western populations. However, many obstacles need to be addressed when implementing CDM in the Asia-Pacific region, which has diverse database structures, healthcare behaviors, regulations, and economic statuses. This symposium will explain the reasons for selecting the common data model as a preferred way to conducting the multi-national study. We will show the our experience of construct the CDM among Asia countries and point out the problems we faced during the process, including complex CDM design, vocabulary mapping and different interpretation by different analysts. We will invite 3 speakers to give us some thought to deal with these problems focusing on how to leverage the complexity of CDM format, the necessity of mapping vocabulary and how to make the protocol easy for understanding.
The topic addresses critical challenges and opportunities in conducting multinational epidemiological research using a common data model (CDM) in Asia-Pacific countries. With rapid advancements in healthcare data collection and analysis technologies, there is a growing need for standardized methods to ensure data consistency, transparency, and reproducibility across diverse healthcare systems.
The symposium will explore practical solutions to these challenges, such as developing a CDM format that balances simplicity with the need to support complex regulatory decision-making processes, examining the necessity of mapping codes during CDM conversion, and facilitating better communication and interpretation of study protocols. By focusing on these issues, the symposium aims to enhance the quality and reliability of real-world evidence generated in the Asian context, which is crucial for informed regulatory decision-making and healthcare policy development.
Furthermore, this topic can help reduce errors encountered by future researchers in constructing CDMs. The insights and experiences shared by experts will provide valuable guidance for researchers and policymakers, fostering greater international collaboration and advancing the field of pharmacoepidemiology in the region.
Speaker
Ms. Hsun Yin Liang
Division of Drug Safety, Taiwan Drug Relief Foundation
Presenter
Biography
Brian Li
Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University
Presenter
Biography
Brian is a PhD student at the School of Pharmacy, National Cheng Kung University, Taiwan. He has expertise in the use of common data model and a variety of healthcare databases across multiple countries in the conduct of international multi-database pharmacoepidemiologic research. He evolved in the project focusing on the effectiveness research of pay-for-performance policies. His research interests lie in safety and comparative effectiveness research, particularly using target trial emulation studies, including the clone-censor-weight approach. He is honored as the oral presenter and spotlight speaker of the ISPE in 2023 and 2024.
Chin Yao Shen
Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University
Presenter
Biography
Mr. Chin-Yao Shen is a senior PhD student at National Cheng Kung University in Tainan, Taiwan. He has a particular interest in cardiovascular diseases, rheumatoid arthritis, and urology, with several publications in these fields. As a pharmacoepidemiologist, his aim is to generate real-world evidence by integrating diverse datasets from Asian countries to support decision-making in regulatory contexts. Chin-Yao focuses on the design and development of distributed data networks in Asia, particularly using the Common Data Model, to produce reliable evidence through descriptive studies, drug surveillance, and comparative effectiveness research."
Assist/Prof Celine Sze Ling Chui
Presenter
Biography
Dr Chui is jointly appointed by the School of Nursing and School of Public Health at HKU. She obtained her PhD degree from the Department of Pharmacology and Pharmacy and completed her post-doctoral training in the School of Public Health at HKU. She had led the design and analysis of studies using electronic health records from multi-databases (including Hong Kong, Taiwan, United Kingdom, Sweden, Australia and New Zealand). She was a visiting scholar (PhD exchange student) at the London School of Hygiene and Tropical Medicine in the United Kingdom and a visiting academic at the Institute of Infection and Immunity Research at City St George’s, University of London.
Dr Chui aims to utilize Big Data from multi-regional/national large healthcare databases and that collected in the community to improve public health. Her current research focuses on cardiovascular disease risk prediction and evaluation using artificial intelligence (AI), Big Data for antimicrobial resistance surveillance, and improving care of people living with dementia. Professor Chui is a Co-principal investigator of AI and Pharmaceuticals in Non-Communicable Diseases at the Laboratory of Data Discovery for Health (D²4H). Professor Chui is also the convener and active member of NeuroGEN (Neurological and Mental Health Global Epidemiology Network), and one of the lead researchers in the CARE Programme, a comprehensive surveillance programme to monitor known and potential adverse events of COVID-19 vaccines.
She is the Principal investigator of a cardiovascular risk prediction model designed for Hong Kong population - P-CARDIAC (Personalised - CARdiovascular DIsease risk Assessment for Chinese) which her work is extensively covered by the media. Dr Chui has an h-index (Scopus) of 30 and has published more than 120 articles in peer-reviewed journals such as The Lancet Infectious Disease, Annals of Internal Medicine, BMJ, JAMA Internal Medicine, and Journal of the American College of Cardiology.
Bin Hong
Sungkyunkwan University
Presenter
Biography
Bin Hong is a senior PhD student in the School of Pharmacy at Sungkyunkwan University, specializing in pharmacoepidemiology. His research interests focus on the comparative effectiveness and safety of drugs for metabolic and cardiovascular diseases, and drug-drug interactions, aiming to bridge the knowledge gap of randomized controlled trials using real-world data. He has published several papers in peer-reviewed journals as the first author, including the Annals of Internal Medicine. Additionally, he has been involved in numerous international research projects, collaborating with experts across the globe to advance the field of pharmacoepidemiology.
Moderator
Suzu Chia-Hsien Chang
Observational Research Senior Manager
Amgen Japan
Edward Chia-Cheng Lai
Educational Program Director
School Of Pharmacy, Institute Of Clinical Pharmacy And Pharmaceutical Sciences
